This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Pfizer/BioNTech: Comirnaty Bivalent Original/Omicron BA.4/BA.5

Pfizer/BioNTech: Comirnaty Bivalent Original/Omicron BA.4/BA.5

Vaccine Type: RNA

This vaccine may also be referred to as BNT162b2 Bivalent (WT/OMI BA.4/BA.5)

About Trial Phases

Phase 1: 1 Trial

NCT05596734

Phase 2: 2 Trials

NCT05472038
United States of America
NCT05543616

Phase 3: 1 Trial

NCT05543616

Registered Trials

NCT05543616
Phase 2/3
Total Enrollment: 2,270
Official Trial Registration:
- NCT05543616(Opens in new tab/window)
NCT05472038
Phase 2
United States of America
Total Enrollment: 700
Official Trial Registration:
- NCT05472038(Opens in new tab/window)
NCT05596734
Phase 1
Total Enrollment: 180
Official Trial Registration:
- NCT05596734(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form